AKAP12 and neoplasm: AKAP12, another ERK1/2 inhibitor [48], was found preferentially upregulated in FGFR tumors, whereas RALT/ERRFI1, an EGFR inhibitor and degradation promoter [47], was strongly overexpressed only in the F2T2↑ tumor, explaining its paradoxical EGFR expression loss.